United-Guardian reported decreased net sales and net income for FY 2025 compared to FY 2024, primarily due to lower cosmetic ingredient sales from distributor inventory overstock and reduced global demand in China. The company noted increased sales in pharmaceuticals and medical lubricants and new marketing initiatives to drive future growth.
Key takeaways
Net sales decreased 13% from $12,181,971 in 2024 to $10,545,468 in 2025
Net income decreased from $3,250,875 ($0.71 per share) in 2024 to $2,105,738 ($0.46 per share) in 2025
Cosmetic ingredient sales declined due to excess inventory at distributor Ashland Specialty Ingredients and reduced demand in China
Pharmaceutical sales increased 15% and medical lubricants sales increased 4% in 2025
Company received approval from two major pharmacy benefit managers for Renacidin inclusion on additional drug formularies
New marketing and distribution agreements for cosmetic ingredients were entered into in 2025